Evaluation of the ability of three commercially available dosimeters to detect systematic delivery errors in step-and-shoot IMRT plans.

BACKGROUND: There is limited data on error detectability for step-and-shoot intensity modulated radiotherapy (sIMRT) plans, despite significant work on dynamic methods. However, sIMRT treatments have an ongoing role in clinical practice. This study aimed to evaluate variations in the sensitivity of three patient-specific quality assurance (QA) devices to systematic delivery errors in sIMRT plans. MATERIALS AND METHODS: Four clinical sIMRT plans (prostate and head and neck) were edited to introduce errors in: Multi-Leaf Collimator (MLC) position (increasing field size, leaf pairs offset (1-3 mm) in opposite directions; and field shift, all leaves offset (1-3 mm) in one direction); collimator rotation (1-3 degrees) and gantry rotation (0.5-2 degrees). The total dose for each plan was measured using an ArcCHECK diode array. Each field, excluding those with gantry offsets, was also measured using an Electronic Portal Imager and a MatriXX Evolution 2D ionisation chamber array. 132 plans (858 fields) were delivered, producing 572 measured dose distributions. Measured doses were compared to calculated doses for the no-error plan using Gamma analysis with 3%/3 mm, 3%/2 mm, and 2%/2 mm criteria (1716 analyses). RESULTS: Generally, pass rates decreased with increasing errors and/or stricter gamma criteria. Pass rate variations with detector and plan type were also observed. For a 3%/3 mm gamma criteria, none of the devices could reliably detect 1 mm MLC position errors or 1 degree collimator rotation errors. CONCLUSIONS: This work has highlighted the need to adapt QA based on treatment plan type and the need for detector specific assessment criteria to detect clinically significant errors.

Quality management in radiation therapy: A 15 year review of incident reporting in two integrated cancer centres.

Fifteen years of reported incidents were reviewed to provide insight into the effectiveness of an Incident Learning System (ISL). The actual error rate over the 15 years was 1.3 reported errors per 1000 treatment attendances. Incidents were reviewed using a regression model. The average number of incidents per year and the number of incidents per thousand attendances declined over time. Two seven-year periods were considered for analysis and the average for the first period (2005-2011) was 6 reported incidents per 1000 attendances compared to 2 incidents for the later period (2012-2018), p < 0.05. SAC 1 and SAC 2 errors have reduced over time and the reduction could be attributed to the quality assurance aspect of IGRT where the incident is identified prior to treatment delivery rather than after, reducing the severity of any potential incidents. The reasoning behind overall reduction in incident reporting over time is unclear but may be associated to quality and technology initiatives, issues with the ISL itself or a change in the staff reporting culture.

Lung organ-at-risk volumes: A survey of practice and the need for a consistent definition in the 4DCT era.

INTRODUCTION: In the 4DCT era, the definition of lung organ-at-risk (OAR) volumes for dose-volume histogram (DVH) calculation is unclear, introducing potential for variability in practice. We aimed to identify definitions used clinically and evaluate the magnitude of DVH differences between these. METHODS: We surveyed Australian & New Zealand departments about lung radiotherapy protocols including lung OAR volume definition. We used these definitions to calculate lung DVHs on 10 patients prescribed lung IMRT (60-66 Gy/30-33 fractions). We calculated mean lung dose (MLD), V20 and V30 for 'Lungs - PTV', 'Lungs - CTV', 'Lungs - iGTV' (internal GTV in all respiratory phases) and 'Lungs - GTV_EX' (expiratory phase). RESULTS: The response rate was 39% (34/88). 14% and 29% of departments did not have a departmental protocol for OAR and tumour volume delineation, respectively. All permutations for lung OAR volumes were used with no clear preference. For conventional radiotherapy (n = 27), this included Lungs alone (n = 1), Lungs - PTV (n = 6), Lungs - CTV (n = 2), Lungs - iGTV (n = 6), Lungs - GTV in single phase (n = 5) and individual clinician preference (n = 7). The different lung OAR volumes resulted in MLD difference ranging from 0.9 to 4.15 Gy, V20 from 1.5% to 6.6% and V30 from 1.34% to 7.11%. The largest differences between subtraction of GTV_EX and iGTV were 0.32 Gy, 0.43% and 0.46% for MLD, V20 and V30, respectively. CONCLUSION: A significant number of departments lacked lung cancer radiotherapy contouring protocols. Lung OAR volume definition was variable between and within departments. Potentially clinically significant differences in lung DVH parameters were seen according to the volume used.

Remote dosimetric auditing of clinical trials: The need for vendor specific models to convert images to dose.

INTRODUCTION: A previous pilot study has demonstrated the feasibility of a novel image-based approach for remote dosimetric auditing of clinical trials. The approach uses a model to convert in-air acquired intensity modulated radiotherapy (IMRT) images to delivered dose inside a virtual phantom. The model was developed using images from an electronic portal imaging device (EPID) on a Varian linear accelerator. It was tuned using beam profiles and field size factors (FSFs) of a series of square fields measured in water tank. This work investigates the need for vendor specific conversion models for image-based auditing. The EPID measured profile and FSF data for Varian (vendor 1) and Elekta (vendor 2) systems are compared along with the performance of the existing Varian model (VM) and a new Elekta model (EM) for a series of audit IMRT fields measured on vendor 2 systems. MATERIALS AND METHODS: The EPID measured beam profile and FSF data were studied for the two vendors to quantify and understand their relevant dosimetric differences. Then, an EM was developed converting EPID to dose in the virtual water phantom using a vendor 2 water tank data and images from corresponding EPID. The VM and EM were compared for predicting vendor 2 measured dose in water tank. Then, the performance of the new EM was compared to the VM for auditing of 54 IMRT fields from four vendor 2 facilities. Statistical significance of using vendor specific models was determined. RESULTS: Observed dosimetry differences between the two vendors suggested developing an EM would be beneficial. The EM performed better than VM for vendor 2 square and IMRT fields. The IMRT audit gamma pass rates were (99.8 ± 0.5)%, (98.6 ± 2.3)% and (97.0 ± 3.0)% at respectively 3%/3 mm, 3%/2 mm and 2%/2 mm with improvements at most fields compared with using the VM. For the pilot audit, the difference between gamma results of the two vendors was reduced when using vendor specific models (VM: P < 0.0001, vendor specific models: P = 0.0025). CONCLUSION: A new model was derived to convert images from vendor 2 EPIDs to dose for remote auditing vendor 2 deliveries. Using vendor specific models is recommended to remotely audit systems from different vendors, however, the improvements found were not major.

Adapting automated treatment planning configurations across international centres for prostate radiotherapy.

BACKGROUND AND PURPOSE: Automated configurations are increasingly utilised for radiotherapy treatment planning. This study investigates whether automated treatment planning configurations are adaptable across clinics with different treatment planning protocols for prostate radiotherapy. MATERIAL AND METHODS: The study comprised three participating centres, each with pre-existing locally developed prostate AutoPlanning configurations using the Pinnacle3® treatment planning system. Using a three-patient training dataset circulated from each centre, centres modified local prostate configurations to generate protocol compliant treatment plans for the other two centres. Each centre applied modified configurations on validation datasets distributed from each centre (10 patients from 3 centres). Plan quality was assessed through DVH analysis and protocol compliance. RESULTS: All treatment plans were clinically acceptable, based off relevant treatment protocol. Automated planning configurations from Centre's A and B recorded 2 and 18 constraint and high priority deviations respectively. Centre C configurations recorded no high priority deviations. Centre A configurations produced treatment plans with superior dose conformity across all patient PTVs (mean = 1.14) compared with Centre's B and C (mean = 1.24 and 1.22). Dose homogeneity was consistent between all centre's configurations (mean = 0.083, 0.077, and 0.083 respectively). CONCLUSIONS: This study demonstrates that automated treatment planning configurations can be shared and implemented across multiple centres with simple adaptations to local protocols.

A remote EPID-based dosimetric TPS-planned audit of centers for clinical trials: outcomes and analysis of contributing factors.

BACKGROUND: A novel remote method for external dosimetric TPS-planned auditing of intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) for clinical trials using electronic portal imaging device (EPID) has been developed. The audit has been applied to multiple centers across Australia and New Zealand. This work aims to assess the audit outcomes and explores the variables that contributed to the audit results. METHODS: Thirty audits were performed of 21 radiotherapy facilities, 17 facilities underwent IMRT audits and 13 underwent VMAT audits. The assessment was based on comparisons between the delivered doses derived from images acquired with EPIDs and planned doses from the local treatment planning systems (TPS). Gamma pass-rate (GPR) and gamma mean value (GMV) were calculated for each IMRT field and VMAT arc (total 268 comparisons). A multiple variable linear model was applied to the GMV results (3%/3 mm criteria) to assess the influence and significance of explanatory variables. The explanatory variables were Linac-TPS combination, TPS grid resolution, IMRT/VMAT delivery, age of EPID, treatment site, record and verification system (R&V) type and dose-rate. Finally, the audit results were compared with other recent audits by calculating the incidence ratio (IR) as a ratio of the observed mean/median GPRs for the remote audit to the other audits. RESULTS: The average (± 1 SD) of the centers' GPRs were: 99.3 ± 1.9%, 98.6 ± 2.7% & 96.2 ± 5.5% at 3%, 3 mm, 3%, 2 mm and 2%, 2 mm criteria respectively. The most determinative variables on the GMVs were Linac-TPS combination, TPS grid resolution and IMRT/VMAT delivery type. The IR values were 1 for seven comparisons, indicating similar GPRs of the remote audit with the reference audits and > 1 for four comparisons, indicating higher GPRs of the remote audit than the reference audits. CONCLUSION: The remote dosimetry audit method for clinical trials demonstrated high GPRs and provided results comparable to established more resource-intensive audit methods. Several factors were found to influence the results including some effect of Linac-TPS combination.

A high DQE water-equivalent EPID employing an array of plastic-scintillating fibers for simultaneous imaging and dosimetry in radiotherapy.

PURPOSE: First measurements of the imaging performance of a novel prototype water-equivalent electronic portal imaging device (EPID) designed for simultaneous imaging and dose verification in radiotherapy and previously characterized by our group for dosimetry are reported. Experiments were conducted to characterize the prototype's imaging performance relative to a standard commercial EPID and Monte Carlo (MC) simulations were performed to quantify the impact of several detector parameters on image quality and to inform the design of a proposed next-generation prototype. METHODS: The prototype EPID utilizes an array of 3 cm long plastic-scintillating fibers in place of the metal plate/phosphor screen in standard EPIDs. Using a clinical 6 MV photon beam, the prototype's modulation transfer function (MTF), noise power spectrum (NPS), and detective quantum efficiency (DQE) were measured and compared to measurements taken using a standard commercial EPID. A sensitivity analysis was then performed using the MC model by quantifying these metrics while varying the values of several geometrical and optical transport parameters that were unspecified by the prototype manufacturer. Finally, the MC model was used to quantify the imaging performance of a proposed next-generation prototype incorporating 1.5 cm long fibers that is better suited for integration with clinical portal imaging and dosimetry systems. RESULTS: The prototype EPID's zero spatial frequency DQE exceeded 3%, more than doubling that measured with the standard EPID (1.25%). This increased DQE was a consequence of using a prototype array detector with a greater equivalent thickness than the combined copper plate and phosphor screen in a standard EPID. The increased thickness of our prototype decreased spatial resolution relative to the standard EPID; however, the prototype EPID NPS was also lower than that measured with the standard EPID across all spatial frequencies. The sensitivity analysis demonstrated that the NPS was strongly affected by the roughness of the boundaries between fiber core and cladding regions. By comparison, the MTF was most sensitive to beam divergence and the presence of air between the fiber array and underlying photodiode panel. Simulations demonstrated that by optimizing these parameters, DQE(0) >4% may be achievable with the proposed next-generation prototype design. CONCLUSIONS: The first measurements characterizing the imaging performance of a novel water-equivalent EPID for imaging and dosimetry in radiotherapy demonstrated a DQE(0) more than double that of a standard EPID. MC simulations further demonstrated the potential for developing a next-generation prototype better suited for clinical translation with even higher DQE.

A survey of modulated radiotherapy use in Australia & New Zealand in 2015.

A survey of radiation oncology medical physics departments across Australia and New Zealand was conducted to assess the usage, commissioning and quality assurance of modulated radiotherapy techniques such as IMRT and VMAT. Survey responses were collected in April-May 2015 to snapshot current practice and historical implementation. The survey asked 142 questions, and is the most detailed survey of its kind published to date. Analysis of results at overall department level, as well as sub-analysis for different equipment and techniques in use, was performed. Results show a high prevalence of IMRT and VMAT in use, and demonstrate the large heterogeneity in clinical practice and experience across the region.

Clinical implementation of an exit detector-based dose reconstruction tool for helical tomotherapy delivery quality assurance.

PURPOSE: The aim of this study was to validate the accuracy of an exit detector-based dose reconstruction tool for helical tomotherapy (HT) delivery quality assurance (DQA). METHODS AND MATERIAL: Exit detector-based DQA tool was developed for patient-specific HT treatment verification. The tool performs a dose reconstruction on the planning image using the sinogram measured by the HT exit detector with no objects in the beam (i.e., static couch), and compares the reconstructed dose to the planned dose. Vendor supplied (three "TomoPhant") plans with a cylindrical solid water ("cheese") phantom were used for validation. Each "TomoPhant" plan was modified with intentional multileaf collimator leaf open time (MLC LOT) errors to assess the sensitivity and robustness of this tool. Four scenarios were tested; leaf 32 was "stuck open," leaf 42 was "stuck open," random leaf LOT was closed first by mean values of 2% and then 4%. A static couch DQA procedure was then run five times (once with the unmodified sinogram and four times with modified sinograms) for each of the three "TomoPhant" treatment plans. First, the original optimized delivery plan was compared with the original machine agnostic delivery plan, then the original optimized plans with a known modification applied (intentional MLC LOT error) were compared to the corresponding error plan exit detector measurements. An absolute dose comparison between calculated and ion chamber (A1SL, Standard Imaging, Inc., WI, USA) measured dose was performed for the unmodified "TomoPhant" plans. A 3D gamma evaluation (2%/2 mm global) was performed by comparing the planned dose ("original planned dose" for unmodified plans and "adjusted planned dose" for each intentional error) to exit detector-reconstructed dose for all three "Tomophant" plans. Finally, DQA for 119 clinical (treatment length <25 cm) and three cranio-spinal irradiation (CSI) plans were measured with both the ArcCHECK phantom (Sun Nuclear Corp., Melbourne, FL, USA) and the exit detector DQA tool to assess the time required for DQA and similarity between two methods. RESULTS: The measured ion chamber dose agreed to within 1.5% of the reconstructed dose computed by the exit detector DQA tool on a cheese phantom for all unmodified "Tomophant" plans. Excellent agreement in gamma pass rate (>95%) was observed between the planned and reconstructed dose for all "Tomophant" plans considered using the tool. The gamma pass rate from 119 clinical plan DQA measurements was 94.9% ± 1.5% and 91.9% ± 4.37% for the exit detector DQA tool and ArcCHECK phantom measurements (P = 0.81), respectively. For the clinical plans (treatment length <25 cm), the average time required to perform DQA was 24.7 ± 3.5 and 39.5 ± 4.5 min using the exit detector QA tool and ArcCHECK phantom, respectively, whereas the average time required for the 3 CSI treatments was 35 ± 3.5 and 90 ± 5.2 min, respectively. CONCLUSION: The exit detector tool has been demonstrated to be faster for performing the DQA with equivalent sensitivity for detecting MLC LOT errors relative to a conventional phantom-based QA method. In addition, comprehensive MLC performance evaluation and features of reconstructed dose provide additional insight into understanding DQA failures and the clinical relevance of DQA results.

Dose discrepancy between planning system estimation and measurement in spine stereotactic body radiation therapy: A case report.

Stereotactic body radiation therapy (SBRT) to treat spinal metastases has shown excellent clinical outcomes for local control. High dose gradients wrapping around spinal cord make this treatment technically challenging. In this work, we present a spine SBRT case where a dosimetric error was identified during pre-treatment dosimetric quality assurance (QA). A patient with metastasis in T7 vertebral body consented to undergo SBRT. A dual arc volumetric modulated arc therapy plan was generated on the Pinnacle treatment planning system (TPS) with a 6 MV Elekta machine using gantry control point spacing of 4°. Standard pre-treatment QA measurements were performed, including ArcCHECK, ion chamber in CTV and spinal cord (SC) region and film measurements in multiple planes. While the dose measured at CTV region showed good agreement with TPS, the dose measured to the SC was significantly higher than reported by TPS in the original and repeat plans. Acceptable agreement was only achieved when the gantry control point spacing was reduced to 3°. A potentially harmful dose error was identified by pre-treatment QA. TPS parameter settings used safely in conventional treatments should be re-assessed for complex treatments.

Sensitivity evaluation of two commercial dosimeters in detecting Helical TomoTherapy treatment delivery errors.

PURPOSE: To assess the sensitivity of two commercial dosimetry systems in detecting Helical TomoTherapy (HT) delivery errors. METHOD: Two commercial dosimeters i) MatriXXEvolution and ii) ArcCHECK® were considered. Ten retrospective nasopharynx HT patients were analysed. For each patient, error plans were created by independently introducing systematic offsets in: a) Jaw width error ±1, ±1.5 and ±2mm, b) Couch speed error ±2%, ±2.5, ±3% and ±4%, and c) MLC Leaf Open Time (MLCLOT) errors (3 separate MLC errors: either leaf 32 open or leaf 42 remains open during delivery, and 4% random reductions in MLCLOT). All error plans, along with the no error plan for each patient, were measured using both dosimeters in the same session. Gamma evaluation (3%/3mm) was applied to quantitatively compare the measured dose from each dosimeter to the treatment planning system. The error sensitivity was quantified as the rate of decrease in gamma pass rate. RESULTS: The gamma pass rate decreases with increase in error magnitude for both dosimeters. ArcCHECK was insensitive for couch speed error up to 2.5% and jaw width error up to -1.5mm while MatriXXEvolution was found to be insensitive to couch speed error up to 2% and couch speed up to -1mm. Both of the detectors show similar sensitivity to all the MLCLOT errors that were clinically relevant. CONCLUSION: No statistically significant (p>0.05) differences exist in detecting the simulated delivery errors between MatriXXEvolution and ArcCHECK dosimeter systems for HT plans. Both dosimeters were able to pick up clinically relevant delivery errors.

Virtual EPID standard phantom audit (VESPA) for remote IMRT and VMAT credentialing.

A virtual EPID standard phantom audit (VESPA) has been implemented for remote auditing in support of facility credentialing for clinical trials using IMRT and VMAT. VESPA is based on published methods and a clinically established IMRT QA procedure, here extended to multi-vendor equipment. Facilities are provided with comprehensive instructions and CT datasets to create treatment plans. They deliver the treatment directly to their EPID without any phantom or couch in the beam. In addition, they deliver a set of simple calibration fields per instructions. Collected EPID images are uploaded electronically. In the analysis, the dose is projected back into a virtual cylindrical phantom. 3D gamma analysis is performed. 2D dose planes and linear dose profiles are provided and can be considered when needed for clarification. In addition, using a virtual flat-phantom, 2D field-by-field or arc-by-arc gamma analyses are performed. Pilot facilities covering a range of planning and delivery systems have performed data acquisition and upload successfully. Advantages of VESPA are (1) fast turnaround mainly driven by the facility's capability of providing the requested EPID images, (2) the possibility for facilities performing the audit in parallel, as there is no need to wait for a phantom, (3) simple and efficient credentialing for international facilities, (4) a large set of data points, and (5) a reduced impact on resources and environment as there is no need to transport heavy phantoms or audit staff. Limitations of the current implementation of VESPA for trials credentialing are that it does not provide absolute dosimetry, therefore a Level I audit is still required, and that it relies on correctly delivered open calibration fields, which are used for system calibration. The implemented EPID based IMRT and VMAT audit system promises to dramatically improve credentialing efficiency for clinical trials and wider applications.

Clinical significance of treatment delivery errors for helical TomoTherapy nasopharyngeal plans - A dosimetric simulation study.

PURPOSE: Develop a framework to characterize helical TomoTherapy (HT) machine delivery errors and their clinical significance. METHOD AND MATERIALS: Ten nasopharynx HT plans were edited to introduce errors in Jaw width (JW), couch speed (CS), gantry period (GP), gantry start position (GSP), multi leaf collimator leaf open times (MLC LOT). In case of MLC LOT only, both systematic and random delivery errors were investigated. Each error type was simulated independently for a range of magnitudes. Dose distributions for the clinical reference plans and the error simulated plans were compared to establish the magnitude for each error type which resulted in a change in clinical tolerance, defined as 5% variation in D95 of PTV70, D0.1cc of spinal cord, D0.1cc of brainstem and the smallest value of either a 10% or 3.6Gy dose variation in mean parotid dose. RESULTS: Dose variation from systematic delivery errors in JW ±0.5mm, CS ranges between -1% to 1.5%, GP ±1s, GSP ranges between -20 to 2.50 and MLC LOT random error up to 2% from the planned value relative to the clinical reference plan was within the set tolerance values for all the patient cohorts. GSP errors and the random MLC LOT errors with up to 10% standard deviation were found to be relatively insensitive compared to other delivery errors. CONCLUSION: This work has established a framework to characterize HT machine delivery errors. This framework could be applied to any patient dataset to determine clinically relevant HT QA tolerances.

In silico investigation of factors affecting the MV imaging performance of a novel water-equivalent EPID.

PURPOSE: A Geant4 model of a novel, water-equivalent electronic portal imaging device (EPID) prototype for radiotherapy imaging and dosimetry utilising an array of plastic scintillating fibres (PSFs) has been developed. Monte Carlo (MC) simulations were performed to quantify the PSF-EPID imaging performance and to investigate design aspects affecting performance for optimisation. METHODS: Using the Geant4 model, the PSF-EPID's imaging performance for 6 MV photon beams was quantified in terms of its modulation transfer function (MTF), noise power spectrum (NPS) and detective quantum efficiency (DQE). Model parameters, including fibre dimensions, optical cladding reflectivity and scintillation yield, were varied to investigate impact on imaging performance. RESULTS: The MC-calculated DQE(0) for the reference PSF-EPID geometry employing 30mm fibres was approximately nine times greater than values reported for commercial EPIDs. When using 10mm long fibres, the PSF-EPID DQE(0) was still approximately three times greater than that of a commercial EPID. Increased fibre length, cladding reflectivity and scintillation yield produced the greatest decreases in NPS and increases in DQE. CONCLUSIONS: The potential to develop an optimised next-generation water-equivalent EPID with MV imaging performance at least comparable to commercial EPIDs has been demonstrated. Factors most important for optimising prototype design include fibre length, cladding reflectivity and scintillation yield.

Superior target volume and organ stability with the use of endorectal balloons in post-prostatectomy radiotherapy.

INTRODUCTION: We investigated the endorectal balloon (ERB) as a method to improve post-prostatectomy clinical target volume (CTV) stability. METHODS: Seventy cone-beam CT (CBCT) obtained during radiotherapy treatment from seven patients treated with an ERB and 68 CBCT from seven patients treated without an ERB were contoured according to published guidelines. CTV was subdivided into superior and inferior CTV; whole rectal volume was subdivided into superior and inferior rectum and anal volume. Concordance index (CI) of CBCT treatment volumes compared with planning volumes was calculated and displacements were measured. RESULTS: Whole rectal, superior and inferior rectum and anal CI were significantly improved with the ERB by 21%, 17%, 26% and 17% respectively (P < 0.0001). Overall CTV and inferior CTV CI was improved by 4% with the ERB (overall CTV P = 0.021; Inferior CTV P < 0.0001). In the ERB cohort, average displacement for superior CTV was 0.37 cm anterior-posterior (AP) and 0.10 cm left-right (LR). Average standard deviation was 0.27 cm AP and 0.11 cm LR. Inferior CTV average displacement was 0.11 cm AP and 0.02 cm LR. Average standard deviation was 0.11 cm AP and 0.02 cm LR. In the non-ERB cohort, average displacement for superior CTV was 0.43 cm AP and 0.10 mm left-right (LR). Average standard deviation was 0.45 cm AP and 0.13 cm LR. Inferior CTV average displacement was 0.16 cm AP and 0.01 cm LR. Average standard deviation was 0.17 cm AP and 0.03 cm LR. There was no statistically significant impact of bladder filling on CTV CI in ERB patients (P = 0.551) as opposed to non-ERB patients (P = 0.0421). CONCLUSION: ERBs in the post-prostatectomy setting resulted in increased rectal and CTV stability while negating the effects of bladder filling on CTV stability.

Feasibility study of a dual detector configuration concept for simultaneous megavoltage imaging and dose verification in radiotherapy.

PURPOSE: To test the feasibility of a dual detector concept for comprehensive verification of external beam radiotherapy. Specifically, the authors test the hypothesis that a portal imaging device coupled to a 2D dosimeter provides a system capable of simultaneous imaging and dose verification, and that the presence of each device does not significantly detract from the performance of the other. METHODS: The dual detector configuration comprised of a standard radiotherapy electronic portal imaging device (EPID) positioned directly on top of an ionization-chamber array (ICA) with 2 cm solid water buildup material (between EPID and ICA) and 5 cm solid backscatter material. The dose response characteristics of the ICA and the imaging performance of the EPID in the dual detector configuration were compared to the performance in their respective reference clinical configurations. The reference clinical configurations were 6 cm solid water buildup material, an ICA, and 5 cm solid water backscatter material as the reference dosimetry configuration, and an EPID with no additional buildup or solid backscatter material as the reference imaging configuration. The dose response of the ICA was evaluated by measuring the detector's response with respect to off-axis position, field size, and transit object thickness. Clinical dosimetry performance was evaluated by measuring a range of clinical intensity-modulated radiation therapy (IMRT) beams in transit and nontransit geometries. The imaging performance of the EPID was evaluated quantitatively by measuring the contrast-to-noise ratio (CNR) and spatial resolution. Images of an anthropomorphic phantom were also used for qualitative assessment. RESULTS: The measured off-axis and field size response with the ICA in both transit and nontransit geometries for both dual detector configuration and reference dosimetry configuration agreed to within 1%. Transit dose response as a function of object thickness agreed to within 0.5%. All IMRT test patterns and clinical IMRT beams had gamma pass rates of ≥98% at 2%/2 mm criteria. In terms of imaging performance, the measured CNR and spatial resolution (f50) were 263.23 ± 24.85 and 0.4025 ± 1.25 × 10(-3) for dual detector configuration and 324 ± 26.65 and 0.4141 ± 1.14 × 10(-3) for reference imaging configuration, respectively. The CNR and spatial resolution were quantitatively worse in the dual detector configuration due to the additional backscatter. The difference in imaging performance was not visible in qualitative assessment of phantom images. CONCLUSIONS: Combining a commercially available ICA dosimetry device with a conventional EPID did not significantly detract from the performance of either device. Further improvements in imaging performance may be achieved with an optimized design. This study demonstrates the feasibility of a dual detector concept for simultaneous imaging and dosimetry in radiation therapy.

Dose calibration of EPIDs for segmented IMRT dosimetry.

The purpose of this study was to investigate the dose response of amorphous silicon (a-Si) electronic portal imaging devices (EPIDs) under different acquisi- tion settings for both open jaw defined fields and segmented intensity-modulated radiation therapy (IMRT) fields. Four different EPIDs were used. Two Siemens and one Elekta plus a standalone Perkin Elmer research EPID. Each was operated with different acquisition systems and settings. Dose response linearity was measured for open static jaw defined fields and 'simple' segmented IMRT fields for a range of equipment and system settings. Six 'simple' segmented IMRT fields were used. The segments of each IMRT field were fixed at 10 × 10 cm2 field size with equal MU per segment, each field having a total of 20 MU. Simultaneous measurements with an ionization chamber array (ICA) and EPID were performed to separate beam and detector response characteristics. Three different pixel calibration meth- ods were demonstrated and compared for an example 'clinical IMRT field'. The dose response with the Elekta EPID for 'simple' segmented IMRT fields versus static fields agreed to within 2.5% for monitor unit (MU) ≥ 2. The dose response for the Siemens systems was difficult to interpret due to the poor reproducibility for segmented delivery, at MU ≤ 5, which was not observed with the standalone research EPID nor ICA on the same machine. The dose response measured under different acquisition settings and different linac/EPID combinations matched closely (≤ 1%), except for the Siemens EPID. Clinical IMRT EPID dosimetry implemented with the different pixel-to-dose calibration methods indicated that calibration at 20 MU provides equivalent results to implementing a ghosting correction model. The nonlinear dose response was consistent across both clinical EPIDs and the standalone research EPID, with the exception of the poor reproducibility seen with Siemens EPID images of IMRT fields. The nonlinear dose response was relatively insensitive to acquisition settings and appears to be primarily due to gain ghosting effects. No additional ghosting correction factor is necessary when the pixel-to- dose calibration factor at small MU calibration method is used. 

Endorectal balloons in the post prostatectomy setting: do gains in stability lead to more predictable dosimetry?

PURPOSE: To perform a comparative study assessing potential benefits of endorectal-balloons (ERB) in post-prostatectomy patients. METHOD AND MATERIALS: Ten retrospective post-prostatectomy patients treated without ERB and ten prospective patients treated with the ERB in situ were recruited. All patients received IMRT and IGRT using kilovoltage cone-beam computed tomography (kVCBCT). kVCBCT datasets were registered to the planning dataset, recontoured and the original plan recalculated on the kVCBCTs to recreate anatomical conditions during treatment. The imaging, structure and dose data were imported into in-house software for the assessment of geometric variation and cumulative equivalent uniform dose (EUD) in the two groups. RESULTS: The difference in location (ΔCOV) for the bladder between planning and each CBCT was similar for each group. The range of mean ΔCOV for the rectum was 0.15-0.58 cm and 0.15-0.59 cm for the non-ERB and ERB groups. For superior-CTV and inferior-CTV the difference between planned and delivered D95% (mean ± SD) for the non-ERB group was 2.1 ± 6.0 Gy and -0.04 ± 0.20 Gy. While for the ERB group the difference in D95% was 8.7 ± 12.6 Gy and 0.003 ± 0.104 Gy. CONCLUSIONS: The use of ERBs in the post-prostatectomy setting did improve geometric reproducibility of the target and surrounding normal tissues, however no improvement in dosimetric stability was observed for the margins employed.

Characterization of a novel EPID designed for simultaneous imaging and dose verification in radiotherapy.

PURPOSE: Standard amorphous silicon electronic portal imaging devices (a-Si EPIDs) are x-ray imagers used frequently in radiotherapy that indirectly detect incident x-rays using a metal plate and phosphor screen. These detectors may also be used as two-dimensional dosimeters; however, they have a well-characterized nonwater-equivalent dosimetric response. Plastic scintillating (PS) fibers, on the other hand, have been shown to respond in a water-equivalent manner to x-rays in the energy range typically encountered during radiotherapy. In this study, the authors report on the first experimental measurements taken with a novel prototype PS a-Si EPID developed for the purpose of performing simultaneous imaging and dosimetry in radiotherapy. This prototype employs an array of PS fibers in place of the standard metal plate and phosphor screen. The imaging performance and dosimetric response of the prototype EPID were evaluated experimentally and compared to that of the standard EPID. METHODS: Clinical 6 MV photon beams were used to first measure the detector sensitivity, linearity of dose response, and pixel noise characteristics of the prototype and standard EPIDs. Second, the dosimetric response of each EPID was evaluated relative to a reference water-equivalent dosimeter by measuring the off-axis and field size response in a nontransit configuration, along with the off-axis, field size, and transmission response in a transit configuration using solid water blocks. Finally, the imaging performance of the prototype and standard EPIDs was evaluated quantitatively by using an image quality phantom to measure the contrast to noise ratio (CNR) and spatial resolution of images acquired with each detector, and qualitatively by using an anthropomorphic phantom to acquire images representative of human anatomy. RESULTS: The prototype EPID's sensitivity was 0.37 times that of the standard EPID. Both EPIDs exhibited responses that were linear with delivered dose over a range of 1-100 monitor units. Over this range, the prototype and standard EPID central axis responses agreed to within 1.6%. Images taken with the prototype EPID were noisier than those taken with the standard EPID, with fractional uncertainties of 0.2% and 0.05% within the central 1 cm(2), respectively. For all dosimetry measurements, the prototype EPID exhibited a near water-equivalent response whereas the standard EPID did not. The CNR and spatial resolution of images taken with the standard EPID were greater than those taken with the prototype EPID. CONCLUSIONS: A prototype EPID employing an array of PS fibers has been developed and the first experimental measurements are reported. The prototype EPID demonstrated a much morewater-equivalent dose response than the standard EPID. While the imaging performance of the standard EPID was superior to that of the prototype, the prototype EPID has many design characteristics that may be optimized to improve imaging performance. This investigation demonstrates the feasibility of a new detector design for simultaneous imaging and dosimetry treatment verification in radiotherapy.

Characterization of optical transport effects on EPID dosimetry using Geant4.

PURPOSE: Current amorphous silicon electronic portal imaging devices (a-Si EPIDs) that are frequently used in radiotherapy applications employ a metal plate/phosphor screen configuration to optimize x-ray detection efficiency. The phosphor acts to convert x rays into an optical signal that is detected by an underlying photodiode array. The dosimetric response of EPIDs has been well characterized, in part through the development of computational models. Such models, however, have generally made simplifying assumptions with regards to the transport of optical photons within these detectors. The goal of this work was to develop and experimentally validate a new Monte Carlo (MC) model of an a-Si EPID that simulates both x-ray and optical photon transport in a self-contained manner. Using this model the authors establish a definitive characterization of the effects of optical transport on the dosimetric response of a-Si EPIDs employing gadolinium oxysulfide phosphor screens. METHODS: The Geant4 MC toolkit was used to develop a model of an a-Si EPID that employs standard electromagnetic and optical physics classes. The sensitivity of EPID response to uncertainties in optical transport parameters was evaluated by investigating their effects on the EPID point spread function (PSF). An optical blur kernel was also calculated to isolate the component of the PSF resulting purely from optical transport. A 6 MV photon source model was developed and integrated into the MC model to investigate EPID dosimetric response. Field size output factors and relative dose profiles were calculated for a set of open fields by separately scoring energy deposited in the phosphor and optical absorption events in the photodiode. These were then compared to quantify effects resulting from optical photon transport. The EPID model was validated against experimental measurements taken using a research EPID. RESULTS: Optical photon scatter within the phosphor screen noticeably broadened the PSF. Variations in optical transport parameters reported in the literature caused fluctuations in the PSF full width at half maximum (FWHM) and full width at tenth maximum (FWTM) of less than 3% and 5%, respectively, confirming model robustness. Greater deviations (up to 9.5% and 36% for FWHM and FWTM, respectively) were observed when optical parameters were largely different from reference values. When scoring energy deposition in the phosphor, measured and calculated output factors agreed within statistical uncertainties and at least 94% of the MC simulated profile data points passed 3%/3 mm γ-index criterion for all field sizes considered. Despite statistical uncertainties in optical simulations arising from computational limitations, no differences were observed between optical and energy deposition profiles. CONCLUSIONS: Simulations demonstrated noticeable blurring of the EPID PSF when scoring optical absorption events in the photodiode relative to energy deposition in the phosphor. However, modeling the standard electromagnetic transport alone should suffice when using MC methods to predict EPID dose-response to static, open 6 MV fields with a standard a-Si photodiode array. Therefore, using energy deposition in the phosphor as a surrogate for EPID dose-response is a valid approach that should not require additional corrections for optical transport effects in current a-Si EPIDs employing phosphor screens.